Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
María J Cejalvo & Javier de la Rubia. (2015) Clinical treatment of newly diagnosed multiple myeloma. Expert Review of Hematology 8:5, pages 595-611.
Read now
Read now
Margarita Blanes, José D. González, Juan J. Lahuerta, Paz Ribas, Ignacio Lorenzo, Blanca Boluda, Miguel A. Sanz & Javier de la Rubia. (2015) Bortezomib-based induction therapy followed by intravenous busulfan–melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma. Leukemia & Lymphoma 56:2, pages 415-419.
Read now
Read now
Massimo Martino, Attilio Olivieri, Massimo Offidani, Ernesto Vigna, Tiziana Moscato, Roberta Fedele, Mauro Montanari, Giuseppe Console, Massimo Gentile, Giuseppe Messina, Giuseppe Irrera & Fortunato Morabito. (2013) Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opinion on Investigational Drugs 22:5, pages 619-634.
Read now
Read now
Articles from other publishers (18)
Sarah Farag, Ulrike Bacher, Barbara Jeker, Myriam Legros, Gaelle Rhyner, Jean-Marc Lüthi, Julian Schardt, Thilo Zander, Michael Daskalakis, Behrouz Mansouri, Chantal Manz & Thomas Pabst. (2022) Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial. Bone Marrow Transplantation 57:6, pages 990-997.
Crossref
Crossref
Fei Gao, Mei-Si Lin, Jie-Shu You, Min-Yue Zhang, Long Cheng, Ke Lin, Peng Zhao & Qi-Yan Chen. (2021) Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis. Cancer Cell International 21:1.
Crossref
Crossref
M. Blanes, J. I. Lorenzo, P. Ribas, A. Jiménez, J. D. González, M. J. Cejalvo, C. Solano, A. Alegre & Javier de la Rubia. (2019) Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma. Annals of Hematology 98:8, pages 2013-2015.
Crossref
Crossref
Sung-Hoon Jung, Je-Jung Lee, Jin Seok Kim, Chang-Ki Min, Kihyun Kim, Yunsuk Choi, Hyeon-Seok Eom, Young Don Joo, Sung-Hyun Kim, Jae-Yong Kwak, Hye Jin Kang, Jae Hoon Lee, Ho Sup Lee, Yeung-Chul Mun, Joon Ho Moon, Sang Kyun Sohn, Seong Kyu Park, Yong Park, Ho-Jin Shin & Sung-Soo Yoon. (2018) Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). Biology of Blood and Marrow Transplantation 24:5, pages 923-929.
Crossref
Crossref
D Sivaraj, W Bacon, G D Long, D A Rizzieri, M E Horwitz, K M Sullivan, Y Kang, Z Li, N J Chao & C Gasparetto. (2017) High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplantation 53:1, pages 34-38.
Crossref
Crossref
Stefan K. Barta, Rishi Jain, Amithaba Mazumder, Jason Carter, Lawrence Almanzar, Roy Browne, Samira Shahnaz, Richard Elkind, David Kaminetzky, Ramakrishna Battini, Olga Derman, Noah Kornblum, Amit Verma & Ira Braunschweig. (2017) Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 17:10, pages 650-657.
Crossref
Crossref
María-Victoria Mateos, Enrique M. Ocio, Bruno Paiva, Laura Rosiñol, Joaquín Martínez-López, Joan Bladé, Juan-José Lahuerta, Ramón García-Sanz & Jesús F. San Miguel. (2015) Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Reviews 29:6, pages 387-403.
Crossref
Crossref
Morie A. Gertz & Craig B. Reeder. 2014. Multiple Myeloma. Multiple Myeloma
101
123
.
Donna ReeceKevin SongRichard LeBlancKhalid MezziAde OlujohungbeDarrell WhiteFaraz ZamanAndrew Belch. (2013) Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma. The Oncologist 18:5, pages 611-618.
Crossref
Crossref
P Kebriaei, T Madden, X Wang, P F Thall, C Ledesma, M de Lima, E J Shpall, C Hosing, M Qazilbash, U Popat, A Alousi, Y Nieto, R E Champlin, R B Jones & B S Andersson. (2012) Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplantation 48:1, pages 26-31.
Crossref
Crossref
Margarita Blanes, Juan J. Lahuerta, José D. González, Paz Ribas, Carlos Solano, Adrían Alegre, Joan Bladé, Jesús F. San Miguel, Miguel A. Sanz & Javier de la Rubia. (2013) Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. Biology of Blood and Marrow Transplantation 19:1, pages 69-74.
Crossref
Crossref
Margarita Blanes & Javier de la Rubia. (2012) Role of autologous bone marrow transplant in multiple myeloma. Current Opinion in Oncology 24:6, pages 733-741.
Crossref
Crossref
Omar S Aljitawi & Joseph P McGuirk. (2012) Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what’s new?. Journal of Comparative Effectiveness Research 1:1, pages 57-70.
Crossref
Crossref
Josien C. Regelink, Hyacintha M. van Roessel, Karin P.M. van Galen, Gert J. Ossenkoppele, Peter C. Huijgens & Sonja Zweegman. (2011) Reply to J. de la Rubia et al. Journal of Clinical Oncology 29:15, pages e450-e450.
Crossref
Crossref
Antonio Palumbo, Michel Attal & Murielle Roussel. (2011) Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival. Clinical Cancer Research 17:6, pages 1253-1263.
Crossref
Crossref
Partow Kebriaei, Timothy Madden, Reza Kazerooni, Xuemei Wang, Peter F. Thall, Celina Ledesma, Yago Nieto, Elizabeth J. Shpall, Chitra Hosing, Muzaffar Qazilbash, Uday Popat, Issa Khouri, Richard E. Champlin, Roy B. Jones & Borje S. Andersson. (2011) Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biology of Blood and Marrow Transplantation 17:3, pages 412-420.
Crossref
Crossref
Amelia A. Langston & Sagar Lonial. 2011. Bortezomib in the Treatment of Multiple Myeloma. Bortezomib in the Treatment of Multiple Myeloma
69
77
.
Murielle RousselPhilippe MoreauAnne HuynhJean-Yves MaryClotaire DanhoDenis CaillotCyrille HulinChristophe FruchartGérald MaritBrigitte PégouriéPascal LenainCarla AraujoBrigitte KolbEdouard RandriamalalaBruno RoyerAnne-Marie StoppaMammoun DibVéronique DorvauxLaurent GarderetClaire Mathiot, Hervé Avet-LoiseauJean-Luc Harousseau & Michel Attal. (2010) Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM). Blood 115:1, pages 32-37.
Crossref
Crossref